Financial health
- Operating income covered interest expense -203.4× in the latest year.
SABS Financials SAB Biotherapeutics, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0 | $13M | — | — | 8.8% | 7.7% | -$46M | — | $11M |
| 2024 | $1M | -$34M | 0.0% | -3244.9% | -131.3% | -77.2% | -$35M | — | $9M |
| 2023 | $2M | -$42M | 0.0% | -1700.6% | -73.6% | -50.3% | -$25M | — | $57M |
| 2022 | $24M | -$19M | 0.0% | -121.0% | -60.3% | -36.8% | -$26M | — | $15M |
| 2021 | $61M | -$17M | 0.0% | -22.0% | -44.5% | -21.1% | -$9M | — | $33M |
| 2020 | $55M | $20M | 0.0% | 37.2% | 51.6% | 35.6% | -$3M | — | $13M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$22M | — | — | -10.5% | -9.4% | -$11M | — | $8M |
| Mar '26 | — | -$19M | — | — | -8.3% | -7.6% | -$15M | — | $21M |
| Dec '25 | — | -$17M | — | — | -11.1% | -9.8% | — | — | $11M |
| Sep '25 | — | $45M | — | — | 27.5% | 24.8% | — | — | $29M |
| Jun '25 | — | -$10M | — | — | -84.2% | -33.6% | — | — | $4M |
| Mar '25 | — | -$5M | — | — | -24.3% | -13.6% | — | — | $6M |
| Dec '24 | $114698 | -$11M | 0.0% | -8726.3% | -43.9% | -25.8% | -$10M | — | $9M |
| Sep '24 | $0 | -$10M | — | — | -28.0% | -19.2% | -$6M | — | $9M |
| Jun '24 | $263137 | -$7M | 0.0% | -3877.0% | -15.9% | -11.9% | -$8M | — | $17M |
| Mar '24 | $944575 | -$5M | 0.0% | -1205.9% | -9.5% | -7.0% | -$11M | — | $14M |
| Dec '23 | $305011 | -$23M | 0.0% | -6187.9% | -39.9% | -27.2% | -$14M | — | $57M |
| Sep '23 | $1M | -$5M | 0.0% | -420.0% | -33.4% | -18.0% | -$5M | — | $2M |
| Jun '23 | $85518 | -$7M | 0.0% | -7573.4% | -34.9% | -19.4% | -$5M | — | $8M |
| Mar '23 | $581101 | -$7M | 0.0% | -1273.8% | -30.1% | -17.2% | -$2M | — | $13M |
| Dec '22 | $2M | -$8M | 0.0% | -363.7% | -25.4% | -15.5% | -$2M | — | $15M |
| Sep '22 | $4M | -$7M | 0.0% | -217.5% | -23.1% | -13.5% | -$8M | — | $8M |
| Jun '22 | $6M | -$5M | 0.0% | -103.0% | -12.9% | -8.0% | -$5M | — | $17M |
| Mar '22 | $12M | $985863 | 0.0% | -56.8% | 2.4% | 1.4% | -$11M | — | $22M |
| Dec '21 | $11M | -$12M | 0.0% | -66.4% | -30.0% | -14.2% | -$7M | — | $33M |
| Sep '21 | $15M | -$4M | 0.0% | -27.2% | -11.6% | -3.5% | $569315 | — | $11M |
Valuation over time
How the market has priced SABS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 25.6× (Dec '25) to 25.5× (Sep '26).
- The price-to-sales ratio has risen from 1.7× (Mar '23) to 273.1× (Nov '25).
P/E
P/S
Frequently asked questions
Is SABS growing its revenue and profit?
See the revenue and net-income charts above for SAB Biotherapeutics, Inc.'s multi-year trend.
How much debt does SABS have?
As of FY2025, SAB Biotherapeutics, Inc. reported — of total debt against $11M of cash; operating income covered interest expense -203.4×.
What is SABS's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is SABS's P/E ratio?
As of Sep '26, SAB Biotherapeutics, Inc. traded at a price-to-earnings ratio of about 25.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.